PubMed Health⌕ Search

Biomedical subjects

J Gumprecht

Publications and source records attributed to J Gumprecht.

At least 19 recordsLinked to original sources
PubMed2001

Human SA gene Pst1 polymorphism and chronic renal failure: results of the family-based study.

BACKGROUND: Because of the heterogeneous aetiology of kidney diseases, interactions between multiple genetic and environmental factors are thought to be involved in the process of progression to end-stage renal disease (ESRD). Raised blood pressure remains a well-established, independent risk factor for a more rapid decline of renal function in various kidney diseases. The aim of the study was to investigate the role of the human SA gene Pst1 polymorphism in the development and/or progression of chronic renal failure (CRF). METHODS: This polymorphism was genotyped in a group of 247 family trios (offspring affected with end-stage renal disease, and both parents): 120 with primary chronic glomerulonephritis, 80 with interstitial nephritis, and 47 with diabetic nephropathy. Transmission/disequilibrium test (TDT) was used to evaluate allele transmission from heterozygous parents to affected offspring. RESULTS: SA gene Pst1 allele transmission did not differ from random proportion of 50:50, with no significant variation in the slope of reciprocal serum creatinine over time between patients with SA Pst1 A1A1, A1A2, and A2A2 genotypes. In addition, no impact of this marker on the rate of progression of CRF in the course of diabetes mellitus, interstitial nephritis, and chronic glomerular nephritis was shown. CONCLUSION: Results of the study suggest no major role of SA gene polymorphism in promoting renal damage. However, the limited numbers of patients having both parents alive included in the analysis might have resulted in insufficient power to detect a minor impact of this polymorphism, especially if such effect is confined to a certain aetiology of CRF.

Adolescent↗
PubMed2000

Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group.

BACKGROUND: Chronic renal failure (CRF) is a complex phenotype that results from an underlying kidney disease and superimposing environmental and genetic factors. The aim of our study was to evaluate the role of polymorphisms in the genes encoding for components of the renin-angiotensin system (RAS) in the development and/or progression of CRF. METHODS: Two hundred forty-seven family trios (patients with CRF and both parents; 120 with primary chronic glomerulonephritis, 80 with interstitial nephritis, and 47 with type 1 diabetes with nephropathy) were examined, and transmission/disequilibrium test (TDT) was used to evaluate allele transmission from heterozygous parents to affected offspring. RESULTS: The D allele of the angiotensin I-converting enzyme (ACE) gene insertion/deletion polymorphism was transmitted significantly more frequently than expected for no association among all examined trios and in the subgroup of patients with interstitial nephritis. The angiotensinogen 235T allele was transmitted significantly more frequently to patients with CRF than expected for no association, but the effect was seen only in patients with interstitial nephritis. The presence of the DD or ID genotype was associated with a faster rate of decline of renal function, which was not observed for the angiotensinogen M235T polymorphism. For chymase gene and angiotensin II receptor type 1 gene, allele transmission did not deviate significantly from a random proportion of 50:50%. CONCLUSIONS: The results of this study suggest that ACE gene insertion/deletion and angiotensinogen M235T polymorphisms contribute to the increased risk for the development of CRF, but the magnitude of the effect within subsets of patients with specific etiologies of CRF must be evaluated further.

Adolescent↗
PubMed2000

[The role of angiotensin I converting enzyme (ACE) Pst 1 polymorphism in the development of chronic renal failure].

Chronic renal failure (CRF) is a complex phenotype, which results from the underlying kidney disease and superimposing environmental and genetic factors. The aim of the study was to evaluate the role of angiotensin converting enzyme gene Pst 1 polymorphism in the development and/or progression of CRF. 247 family trios (patients with CRF and both parents): 120 with primary chronic glomerulonephritis, 80 with interstitial nephritis and 47 with diabetic nephropathy were examined, and transmission/disequilibrium test (TDT) was used to evaluate allele transmission from heterozygous parents to affected off-spring. No significant deviation from random transmission of the examined ACE gene Pst 1 alleles was observed, as well as no impact of this marker on the rate of progression of chronic renal failure.

Adult↗
PubMed1999

Polymorphisms in the genes encoding for human kinin receptors and the risk of end-stage renal failure: results of transmission/disequilibrium test. The End-Stage Renal Disease Study Group.

There is evidence that environmental factors and genetic predisposition affect the development of end-stage renal disease (ESRD). The role of kinin peptides in renal pathology has been also suggested, and a nephroprotective effect of kinins, mediated by B1 and B2 kinin receptors, has been postulated. Recently, two novel sequence differences in the B1R gene were identified, and the C allele of the G-->C substitution at position -699 in the promoter region of the B1R gene was found to be less frequent among patients with ESRD compared with healthy control subjects. In this study, the association between B1R and B2R polymorphisms and ESRD was examined using a family-based study design: transmission/disequilibrium test. B1R gene G-->C substitution at position -699 in the promoter region and B2R gene C-->T transition at position 181 in exon 2 were genotyped in 247 family trios: offspring affected with ESRD and both parents. The less common alleles of both polymorphisms (B1R C allele and B2R T allele) were transmitted from heterozygous parents to offspring affected with ESRD less frequently than expected (37 and 36%, respectively; P < 0.05). In conclusion, results obtained in this study support a hypothesis of the protective role of bradykinin receptor gene polymorphisms in the development of ESRD.

Adolescent↗
PubMed1999

[Platelet aggregation test in specific immunotherapy].

The aim of study was to investigate the effect of a specific immunotherapy (sIT) on the results of the platelet aggregation test (agregometr, chronolog Corp. Broomall, Pa model 345) in patients with inhalant allergy. The trial consisted of 57 patients with seasonal allergic rhinitis (exclusively allergic to grass pollens) and 55 patients with perennial allergic rhinitis sensitive to house dust mite Dermatophagoides pteronyssinus. sIT was applied in only 29 patients suffering from pollinosis and 27 sensitive to house dust mite. The remaining patients were subjected to routine pharmacotherapy alone. The control group consisted of 30 laboratory workers with no history of atopy. Platelet aggregation test was performed before sIT and after 2 years course of treatment and finally revealed the partial improvement of the impaired aggregation capacity of platelets which suggest their involvement in the mechanism of sIT. There was no correlation between the platelets function and IgE serum level and the clinical efficacy of sIT as well.

Adolescent↗
PubMed1997

[Activity of sodium-lithium cotransport in erythrocytes of patients with diabetes mellitus type I (IDDM) complicated by diabetic nephropathy in the renal failure stage].

Sodium-lithium countertransport (SLC) in erythrocytes represents one of the transmembrane sodium transport systems. SLC activity is elevated in arterial hypertension, diabetes mellitus type I (IDDM) complicated with nephropathy, hyperlipidemia, hyperuricemia and pregnancy. Increase of SLC is considered as a genetic marker of primary arterial hypertension. In present paper SLC was assessed in 12 patients with IDDM without nephropathy (group I), 12 patients with IDDM complicated with diabetic nephropathy on hemodialytic treatment (group II), 15 patients treated with haemodialysis due to non-diabetic nephropathy (group III) and 12 healthy subjects (group IV). All groups were matched in respect of age. Serum creatinine concentration and inulin clearance were similar in groups I and IV as well as in groups II and III. SLC was assessed according to method described by Canessa and coworkers (1980). SLC activity in group II (0.60 mmol/l litre of erythrocytes/h; 0.43-0.94; 0.28-1.22) (median, 25%-75%, min.-max.) was significantly higher than in other groups-group I (0.30; 0.20-0.38; 0.12-0.57), group III (0.24; 0.16-0.33; 0.11-0.38) and group IV (0.20; 0.15-0.25; 0.12-0.27). In 3 patients of group I the values were higher than in all examined of groups III and IV and approximated to mean values of group II. The results confirm a significant rise of SLC activity in patients with IDDM complicated with end-stage diabetic nephropathy. SLC activity in end-stage renal disease due to non-diabetic nephropathy does not differ from values in healthy subjects. It seems that elevated SLC activity in IDDM might be a genetic marker foretelling development of nephropathy.

Adult↗
PubMed1996

[Prolactin secretion in diabetic nephropathy of patients with diabetes mellitus type I (IDDM)].

Disturbances of prolactin secretion occur both in the chronic renal failure and in diabetes mellitus. The study aimed to investigate if the diabetic nephropathy as a cause of chronic renal failure disturbs prolactin secretion. The study was conducted in 5 groups of patients: group I-12 patients with IDDM without diabetic nephropathy; group II-12 patients with IDDM with diabetic nephropathy treated conservatively; group III-16 patients with chronic renal failure of non-diabetic origin; group IV-12 patients with IDDM with end stage renal failure in the course of diabetic nephropathy treated with haemodialysis; group V-16 patients with end stage renal failure of non diabetic origin treated with haemodialysis. 12 healthy subjects served as the control group. In all investigated groups as well as in the control group the TRH test was performed. The mean serum prolactin concentration was estimated in the investigated groups just before the intravenous TRH injection and then after 15, 30, 45, 60 and 120 minutes. The mean area over the basic value (AOBV) of prolactin was also assessed. The patients with IDDM without diabetic nephropathy did not differ from healthy subjects both in the basic and TRH induced prolactin secretion. Basic and TRH induced prolactin secretion in patients with diabetic nephropathy both conservatively treated and treated with haemodialysis were lower than in patients with the same stage of chronic renal failure of non-diabetic origin.

Adult↗
PubMed1996

[Effects of opiate receptor blockade with naloxone on prolactin (PRL) secretion in patients with diabetes type I (IDDM) with chronic renal failure treated with hemodialysis (HD)].

The aim of the study was to answer the questions: 1) does the prolactin secretion in the TRH test (0.4 mg i.v.) differ in haemodialyzed patients with diabetes nephropathy in the end stage renal failure in comparison to haemodialyzed chronic renal failure patients with non-diabetic nephropathy and healthy subjects; 2) does the opiate receptors blockade with naloxone (2 mg i.v.) modify the prolactin secretion during the TRH test in those patients. 39 subjects were studied. The patients were divided into three groups: group I: 12 haemodialyzed patients with IDDM and diabetic nephropathy in the end stage renal failure, group II: 15 haemodialyzed chronic renal patients with non-diabetic nephropathy and the control group: 12 healthy persons. The basic prolactin secretion and area over basic value (AOBV) of the prolactin were estimated. Prolactin concentration was measured by LIA. 1) The basic prolactin secretion was significantly higher in the patients with chronic renal failure. 2) The basic prolactin secretion in IDDM patients with diabetic nephropathy in the end stage renal failure treated with haemodialysis was significantly lower than in haemodialyzed patients with chronic renal failure of non-diabetic etiology. 3) TRH and TRH with naloxone caused significant increase of prolactin secretion in all investigated groups, but the increase is significantly lower in chronic renal failure patients than in healthy subjects. 4) Naloxone decreases significantly the prolactin secretion during TRH test only in haemodialyzed patients with chronic renal failure of non-diabetic etiology.

Adult↗
PubMed1995

[Pregnancy course in women with terminal kidney failure treated with hemodialysis].

According to the European Dialysis and Transplantation Association at least 250 patients on each 1 million of inhabitants in Europe is treated with renal replacement therapy. One can assumed that if only half of above mentioned are women then from 5 to 10 of them can conceive pregnant. It's likely that number of pregnant women with end-stage renal disease depending on different forms of renal replacement therapy will increase. These facts determined us to present study concerning to course of pregnancy in women with end-stage renal disease treated with haemodialysis.

Female↗
PubMed1995

[Level of total plasma carnitine in patients with chronic renal failure in the course of diabetes and other etiologies treated with hemodialysis].

In uraemic patients disturbances in carnitine metabolism are observed. Aim of the study was to assess total carnitine level in haemodialyzed patients and influence of dialyzer type on this level before, during and after haemodialysis (HD). We examined 46 patients divided into 3 groups: I--16 non-diabetic uraemic patients haemodialyzed using polysulfone dialyzer; II--10 diabetic patients haemodialyzed using polysulfone dialyzer, III--20 non-diabetic uraemic patients haemodialyzed with cuprophane dialyzer. Total plasma carnitine level was estimated using colorimetric method according to Wieland et al. Total carnitine level in diabetic haemodialyzed patients was significantly lower comparing to non-diabetic ones but in both groups a significant decrease during HD was present. Dialyzer type had no influence on carnitine elimination.

Adult↗
PubMed1994

[Concentrations of lead in blood of patients with chronic renal failure].

UNLABELLED: Several groups have reported increased blood lead (Pb) concentrations in patients with chronic renal failure (CRF) and haemodialysed but normal concentrations were observed by the others. The present study aimed to assess: 1. Pb concentrations in patients with CRF and influence of the haemodialysis on these concentrations. 2. The influence of the erythropoietin (EPO) therapy on the Pb concentrations. 3. The influence of long-term haemodialysis therapy on the Pb concentrations. 101 patients with CRF and 23 healthy subjects were examined. Patients with CRF were divided into two groups: nonhaemodialysed (group I) and haemodialysed (group II). Group two consisted of some subgroups: treated with EPO;--without EPO therapy;--haemodialysed 1-50 months;--51-100 months and > 100 months. Creatinine, Pb, haemoglobin and haematocrit concentrations were measured in all examined patients. Significantly higher Pb concentrations in CRF patients comparing to healthy subjects were found. Among CRF patients significantly lower Pb concentrations were observed in group I and did not differ from those in the control group. After haemodialysis Pb blood concentrations significantly decreased in all examined subgroups. In EPO subgroup in comparison with CRF patients without EPO therapy lower but not significantly Pb concentrations were observed. No significant changes between short and long-term haemodialysed patients were found. CONCLUSIONS: 1. Blood lead concentrations are significantly higher in CRF patients in comparison with healthy subjects. 2. In CRF patients a slight Pb concentration decrease after haemodialysis is observed. 3. EPO treatment has no influence on Pb blood concentrations in examined patients. 4. Long-term haemodialysis treatment has only a slight influence on Pb concentrations in CRF patients.

Adult↗
PubMed1993

[Does hypoglycemic treatment with gliclazide and gliquidone affect platelet function in type II diabetic patients?].

The estimation of the influence of gliclazide and gliquidone treatment on platelet function in type II diabetic patients was undertaken in the study. Aggregation parameters were assessed before and after the change of hypoglycemic therapy. Gliclazide was applied in the group I (11 patients, mean age 63.1 +/- 7.22 years, duration of diabetes 5.63 +/- 2.98 years), group II (19 patients, mean age 58.3 +/- 12.4 years, duration of diabetes 7.1 +/- 2.4) received gliquidone. The reference group consisted of 10 healthy volunteers (mean age 51.7 +/- 6.9). Aggregation parameters (threshold ADP concentration, intensity and velocity of the aggregation) were measured in examined groups of subjects. Metabolic control was estimated basing upon spectrophotometric measurement of fructosamine level. Significant increase in threshold ADP concentration (1.89 +/- 0.47 mumol/l before and 2.36 +/- 0.58 mumol/l after the treatment change p < 0.05) in group II was found. Threshold ADP concentration did not change significantly in group I (2.5 +/- 0.8 mumol/l before v 2.14 +/- 0.68 mumol/l after treatment). Significant decrease in the aggregation intensity was found in both groups (in group I 8.48 +/- 1.7 before v 6.39 +/- 2.17 after; in group II 7.35 +/- 1.73 before v 6.05 +/- 1.6 after 1 month treatment--both p < 0.05). The aggregation velocity did not change significantly (group I 61. +/- 11 before v 51.3 +/- 18.7 after, group II 63.2 +/- 14.8 and 62.8 +/- 13.7 respectively). Reference group values were ADP 2.7 +/- 0.16, intensity 6.22 +/- 0.53, velocity 63.2 +/- 2.2.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1993

[Platelet aggregation and receptor expression of low affinity to IgE (Fc epsilon RII CD23) in patients with seasonal allergic rhinitis].

In 12 patients with pollinosis analysis of platelet function was carried out. Platelet function was assessed basing on the thromboelastogram curve and aggregation capability induced by ADP. Total serum IgE levels, as well as, specific antibodies to grass pollens, IgE and IgG4 levels and circulating receptor of low IgE affinity (sFc epsilon RII/sCD23) were also analysed. The study was carried out in a dynamic state, during natural allergen exposition and natural remission. A significant correlation was found between loss of platelet function and sCD23 levels. The observed relations were not influenced by seasonal changes.

Adolescent↗